Experimental cell therapy tested for Tough-to-Treat autoimmune conditions
NCT ID NCT07122076
Summary
This early-stage study is testing the safety of an experimental cell therapy called GT719 injection in people with moderate to severe autoimmune diseases that haven't responded to standard treatments. The study will enroll 10 participants with conditions like lupus, scleroderma, or inflammatory muscle disease to see if the treatment is safe and how their bodies respond to it. Researchers will monitor participants closely for side effects and look for early signs that the treatment might help control their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Changzheng Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.